PeptideLabs Logo
PeptideLabs
Quality Documentation
Back to all 64 profiles
Community/research information onlyNot FDA/EMA approvedWADA

Community protocol · CJC-1295 no DAC

CJC-1295 no DAC: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: CJC-1295 without DAC · Modified GRF 1-29 · Mod GRF

Sources checked: 27 August 2026

Important safety and liability notice

This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

CJC-1295 no DAC

Distinguished online from the DAC version and discussed for growth-hormone signalling; approval and confirmed safety are lacking.

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amounts, timing and cycles

Community/research information only

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: preclinical.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitution and U-100 conversion

Reconstitution calculator

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

Reconstitution calculator

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

50

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Shorter-acting GHRH analogue without the drug-affinity complex

CJC-1295 no DAC is classified as “Shorter-acting GHRH analogue without the drug-affinity complex”. Distinguished online from the DAC version and discussed for growth-hormone signalling; approval and confirmed safety are lacking. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

GHRH analogue

This examines whether a growth hormone-releasing hormone analogue prompts the pituitary gland to release its own growth hormone, like a signal instructing the gland to release. Researchers measure growth hormone and IGF-1 levels in blood.

02

Growth hormone signalling blend

This studies how several substances that each stimulate growth hormone release are combined by vendors, similar to pressing several buttons at once for the same effect. Individual agents are usually studied, not the combined product.

03

Growth-axis amplification

Researchers study how a substance amplifies the natural hormone chain from brain to pituitary to growth hormone, rather than supplying growth hormone directly. Hormone levels over time and muscle or fat mass are measured.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Bodybuilding forums

Here, muscle growth, strength gains, and recovery times are compared between different growth and repair peptides, often based on personal training logs. Vendor and user claims about muscle gains are anecdotal experience, not controlled study results.

Anti-aging forums

Combinations of growth-axis, mitochondrial, and skin peptides are compared here with the goal of influencing visible or felt signs of ageing, often documented personally over years. Anecdotes and vendor advertising about slowed ageing are not scientific proof.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and risk boundaries

  • Interference with GH, IGF-1 or other hormone axes may cause oedema, joint or nerve symptoms, glucose intolerance, blood-pressure and hormonal changes; dependable human data are absent for many research substances.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • Active or previous malignancy, uncontrolled diabetes, intracranial disease, pregnancy/breastfeeding and hormone-sensitive disease require specialist assessment; approved products have specific contraindications.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • In medically justified use, IGF-1, fasting glucose/HbA1c, blood pressure, weight/oedema, thyroid and indication-specific hormones may be relevant; this is not a self-testing schedule.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclinical

Approval and confirmed safety are lacking for both variants alike.

Published evidence

Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.

Without the drug-affinity-complex binding, this variant acts markedly shorter than CJC-1295 with DAC.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile